June 2015

Dr. Arruda is a hematology researcher at The Children's Hospital of Philadelphia and an associate professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. His laboratory focuses on gene-based strategies for the treatment of bleeding and thrombotic diseases.

Treating hemophilia A with primary prophylaxis is more cost effective than on-demand treatment, according to a study published in The Scientific World Journal.

Simoctocog alfa has no demonstrated benefit for hemophilia A treatment, according to research from the German Institute for Quality and Efficiency in Health Care.

Global companies collaborate to seek long-term, stable treatment for both hemophilia A and B.

A new drug from Baxter has been found safe and efficacious for hemophilia A patients aged 12 years or older in a phase 3 trial.

Treatment for hemophilia A and B patients with inhibitors to factor VIII or factor IX has been submitted as an Investigational New Drug to the FDA.

An aging population of hemophilia patients is at risk for various cardiovascular diseases.